A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.

MLA

Lukey, Pauline T., et al. “A Randomised, Placebo-Controlled Study of Omipalisib (PI3K/MTOR) in Idiopathic Pulmonary Fibrosis.” The European Respiratory Journal, vol. 53, no. 3, Mar. 2019. EBSCOhost, https://doi.org/10.1183/13993003.01992-2018.

APA

Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P., Paul, L., Woodcock, H. V., Toshner, R., Saunders, P., Molyneaux, P. L., Thielemans, K., Wilson, F. J., Mercer, P. F., Chambers, R. C., … Maher, T. M. (2019). A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. The European Respiratory Journal, 53(3). https://doi.org/10.1183/13993003.01992-2018

Chicago

Lukey, Pauline T, Stephen A Harrison, Shuying Yang, Yim Man, Beverley F Holman, Alaleh Rashidnasab, Gabrielle Azzopardi, et al. 2019. “A Randomised, Placebo-Controlled Study of Omipalisib (PI3K/MTOR) in Idiopathic Pulmonary Fibrosis.” The European Respiratory Journal 53 (3). doi:10.1183/13993003.01992-2018.